Oculis Holding AG (NASDAQ:OCS) Short Interest Down 21.0% in April

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 25,600 shares, a drop of 21.0% from the March 31st total of 32,400 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

OCS has been the topic of several research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research note on Tuesday, March 19th. Wedbush reiterated an “outperform” rating and issued a $29.00 target price on shares of Oculis in a research report on Wednesday, March 6th. HC Wainwright cut their price target on Oculis from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Robert W. Baird decreased their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $29.14.

Oculis Stock Up 0.6 %

Oculis stock traded up $0.07 during trading hours on Friday, hitting $12.02. The company had a trading volume of 88,399 shares, compared to its average volume of 71,733. The company has a 50-day moving average price of $11.85 and a two-hundred day moving average price of $11.24. Oculis has a 1 year low of $9.05 and a 1 year high of $14.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.29 and a quick ratio of 5.29.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, analysts forecast that Oculis will post -1.72 earnings per share for the current year.

Institutional Trading of Oculis

A number of hedge funds have recently bought and sold shares of OCS. Barclays PLC purchased a new position in shares of Oculis in the 2nd quarter worth approximately $44,000. Wolverine Asset Management LLC purchased a new position in Oculis in the third quarter worth $77,000. Searle & CO. acquired a new position in shares of Oculis during the fourth quarter worth $112,000. Compagnie Lombard Odier SCmA lifted its holdings in shares of Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the last quarter. Finally, abrdn plc acquired a new stake in shares of Oculis in the 4th quarter worth $15,980,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.